Each Film Coated Tablet contains Atorvastatin calcium trihydrate 10.82mg Equivalent to Atorvastatin 10mg + Ezetimibe 10mg.
Carton box containing 3 Alu/Alu Blisters each of 10 tablets & insert leaflet
Each Film Coated Tablet contains Atorvastatin calcium trihydrate 21.64mg equivalent to Atorvastatin 20mg + Ezetimibe 10mg.
Each box containing 3 Alu/Alu Blisters each of 10 tablets & insert leaflet.
Atrozemb® contains a cholesterol absorption inhibitor and an HMG-CoA reductase inhibitor (statin) and is indicated as adjunctive therapy to diet to:
• reduce elevated total-C, LDL-C, Apo B, TG, and non-HDL-C, and to increase HDL-C in patients with primary (heterozygous familial and non-familial) hyperlipidemia or mixed hyperlipidemia.
• reduce elevated total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH), as an adjunct to other lipidlowering treatments.
Mechanism of Action
Competitive inhibition of HMG CoA reductase, the rate-limiting step in cholesterol synthesis.
Selectively inhibits absorption of dietary and biliary cholesterol in the small intestine.
One film-coated tablet is to be taken orally once daily for the treatment of primary hyperlipidemia and homozygous familial hypercholesterolemia
Limitation of Use
• No incremental benefit of Atrozemb on cardiovascular morbidity and mortality over and above that demonstrated for atorvastatin has been established. Atrozemb has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias.